High prevalence of hepatitis C virus infection in Belgian intravenous drug users and potential role of the "cotton-filter" in transmission: the GEMT Study.

IF 1.5 4区医学 Q2 Medicine

Acta Gastro-Enterologica Belgica Pub Date : 2000-04-01

B Denis, M Dedobbeleer, T Collet, J Petit, M Jamoulle, A Hayani, R Brenard

{"title":"High prevalence of hepatitis C virus infection in Belgian intravenous drug users and potential role of the \"cotton-filter\" in transmission: the GEMT Study.","authors":"B Denis, M Dedobbeleer, T Collet, J Petit, M Jamoulle, A Hayani, R Brenard","doi":"","DOIUrl":null,"url":null,"abstract":"Aims: To estimate viral seroprevalences for HCV, HBV and HIV among belgian intravenous (IVDU) and non intravenous (non-IVDU) drug users; to assess risk factors for HCV infection in IVDU; to assess feasibility of chronic hepatitis C follow-up in this population.Design: Cross-sectional study. Demographic and behavioural characteristics were obtained by a standardized questionnaire. Serum samples were tested for HCV, HBV and HIV.Subjects and setting: 329 patients (244 IVDU and 85 non-IVDU) attending ten general practitioners in 1995.Results: HCV seroprevalence was 78.3%; it was 35.7% for HBV and 0.9% for HIV in IVDU, vs 2.4%, 8.3% and 0%, respectively, in non-IVDU. In logistic regression analysis, independent risk factors for HCV infection were: 1/sharing of syringes and/or of \"cottons\" used as filters (adjusted prevalence odds ratio [POR] = 31.7; 95% confidence interval [CI] = 9.8-102.5), 2/duration of injecting upper than one month (adjusted POR = 8.6; CI = 3.0-24.7) and 3/age (adjusted POR = 1.2 by year of difference; CI = 1.0-1.3). A biochemical follow-up was obtained in 70% of HCV seropositive users; 79.5% of them had chronic hepatitis C (mean value of ALT = 3.5 times upper normal value, range 1.1-23.0). Among these, 24.7% went through liver biopsy during the three years follow-up period of the study.Conclusions: HCV seroprevalence is very high among belgian IVDU. Prevention strategies have to focus on neophytes injectors. They must be urgently revisited for what concern needles/syringes exchange programs: \"cottons\" must be included. Follow-up and treatment of chronic hepatitis C seem to be poorly effective among drug users.","PeriodicalId":50942,"journal":{"name":"Acta Gastro-Enterologica Belgica","volume":"63 2","pages":"147-53"},"PeriodicalIF":1.5000,"publicationDate":"2000-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Gastro-Enterologica Belgica","FirstCategoryId":"3","ListUrlMain":"","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Aims: To estimate viral seroprevalences for HCV, HBV and HIV among belgian intravenous (IVDU) and non intravenous (non-IVDU) drug users; to assess risk factors for HCV infection in IVDU; to assess feasibility of chronic hepatitis C follow-up in this population.

Design: Cross-sectional study. Demographic and behavioural characteristics were obtained by a standardized questionnaire. Serum samples were tested for HCV, HBV and HIV.

Subjects and setting: 329 patients (244 IVDU and 85 non-IVDU) attending ten general practitioners in 1995.

Results: HCV seroprevalence was 78.3%; it was 35.7% for HBV and 0.9% for HIV in IVDU, vs 2.4%, 8.3% and 0%, respectively, in non-IVDU. In logistic regression analysis, independent risk factors for HCV infection were: 1/sharing of syringes and/or of "cottons" used as filters (adjusted prevalence odds ratio [POR] = 31.7; 95% confidence interval [CI] = 9.8-102.5), 2/duration of injecting upper than one month (adjusted POR = 8.6; CI = 3.0-24.7) and 3/age (adjusted POR = 1.2 by year of difference; CI = 1.0-1.3). A biochemical follow-up was obtained in 70% of HCV seropositive users; 79.5% of them had chronic hepatitis C (mean value of ALT = 3.5 times upper normal value, range 1.1-23.0). Among these, 24.7% went through liver biopsy during the three years follow-up period of the study.

Conclusions: HCV seroprevalence is very high among belgian IVDU. Prevention strategies have to focus on neophytes injectors. They must be urgently revisited for what concern needles/syringes exchange programs: "cottons" must be included. Follow-up and treatment of chronic hepatitis C seem to be poorly effective among drug users.

本刊更多论文

比利时静脉注射吸毒者丙型肝炎病毒感染的高流行率和“棉花过滤器”在传播中的潜在作用:GEMT研究

目的:估计比利时静脉(IVDU)和非静脉(非IVDU)吸毒者中HCV、HBV和HIV的血清病毒患病率;评估IVDU中HCV感染的危险因素;评估慢性丙型肝炎患者随访的可行性。设计:横断面研究。通过标准化问卷调查获得人口统计学和行为特征。对血清样本进行HCV、HBV和HIV检测。对象和环境:1995年，329例患者(244例IVDU和85例非IVDU)就诊于10名全科医生。结果:HCV血清阳性率为78.3%;IVDU组HBV感染率为35.7%，HIV感染率为0.9%，而非IVDU组分别为2.4%，8.3%和0%。在logistic回归分析中，HCV感染的独立危险因素为:1/共用注射器和/或使用过滤器的“棉花”(调整后的患病率优势比[POR] = 31.7;95%可信区间[CI] = 9.8-102.5)， 2/注射时间大于1个月(调整后的POR = 8.6;CI = 3.0-24.7)和3/年龄(按年差调整后的POR = 1.2;Ci = 1.0-1.3)。70%的HCV血清阳性使用者进行了生化随访;慢性丙型肝炎患者占79.5% (ALT平均值=正常值上值的3.5倍，范围1.1 ~ 23.0)。其中，24.7%的患者在研究的3年随访期间进行了肝活检。结论:比利时IVDU人群HCV血清阳性率较高。预防战略必须侧重于新手注射者。必须紧急重新审视它们，因为它们涉及针头/注射器交换计划:“棉花”必须包括在内。慢性丙型肝炎的随访和治疗在吸毒者中似乎效果不佳。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Acta Gastro-Enterologica Belgica 医学-胃肠肝病学

CiteScore

2.80

自引率

20.00%

发文量

审稿时长

>12 weeks

期刊介绍： The Journal Acta Gastro-Enterologica Belgica principally publishes peer-reviewed original manuscripts, reviews, letters to editors, book reviews and guidelines in the field of clinical Gastroenterology and Hepatology, including digestive oncology, digestive pathology, as well as nutrition. Pure animal or in vitro work will not be considered for publication in the Journal. Translational research papers (including sections of animal or in vitro work) are considered by the Journal if they have a clear relationship to or relevance for clinical hepato-gastroenterology (screening, disease mechanisms and/or new therapies). Case reports and clinical images will be accepted if they represent an important contribution to the description, the pathogenesis or the treatment of a specific gastroenterology or liver problem. The language of the Journal is English. Papers from any country will be considered for publication. Manuscripts submitted to the Journal should not have been published previously (in English or any other language), nor should they be under consideration for publication elsewhere. Unsolicited papers are peer-reviewed before it is decided whether they should be accepted, rejected, or returned for revision. Manuscripts that do not meet the presentation criteria (as indicated below) will be returned to the authors. Papers that go too far beyond the scope of the journal will be also returned to the authors by the editorial board generally within 2 weeks. The Journal reserves the right to edit the language of papers accepted for publication for clarity and correctness, and to make formal changes to ensure compliance with AGEB’s style. Authors have the opportunity to review such changes in the proofs.